In the last trading session, 1.36 million shares of the Procept BioRobotics Corp (NASDAQ:PRCT) were traded, and its beta was 1.07. Most recently the company’s share price was $62.53, and it changed around $1.63 or 2.68% from the last close, which brings the market valuation of the company to $3.43B. PRCT currently trades at a discount to its 52-week high of $103.81, offering almost -66.02% off that amount. The share price’s 52-week low was $45.56, which indicates that the current value has risen by an impressive 27.14% since then. We note from Procept BioRobotics Corp’s average daily trading volume that its 10-day average is 0.8 million shares, with the 3-month average coming to 891.10K.
Procept BioRobotics Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.36. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended PRCT as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Procept BioRobotics Corp is expected to report earnings per share of -0.49 for the current quarter.
Procept BioRobotics Corp (NASDAQ:PRCT) trade information
Instantly PRCT has showed a green trend with a performance of 2.68% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 64.38 on recent trading dayincreased the stock’s daily price by 2.87%. The company’s shares are currently down -22.34% year-to-date, but still up 9.64% over the last five days. On the other hand, Procept BioRobotics Corp (NASDAQ:PRCT) is -4.02% down in the 30-day period. We can see from the shorts that 5.08 million shares have been sold at a short interest cover period of 5.52 day(s).
The consensus price target as assigned by Wall Street analysts is $105, which translates to bulls needing to increase their stock price by 40.45% from its current value. Analyst projections state that PRCT is forecast to be at a low of $105 and a high of $105.
Procept BioRobotics Corp (PRCT) estimates and forecasts
The year-over-year growth rate is expected to be 43.28%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 65.4M in revenue for the current quarter. 9 analysts expect Procept BioRobotics Corp to make 76.4M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 44.54M and 53.35M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 46.85%. Forecasts for the next quarter put sales growth at 43.21%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.56%. Procept BioRobotics Corp earnings are expected to increase by 13.69% in 2025, but the outlook is positive 37.06% per year for the next five years.
PRCT Dividends
Procept BioRobotics Corp’s next quarterly earnings report is expected to be released on 2025-Feb-24.
Procept BioRobotics Corp (NASDAQ:PRCT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.65% of Procept BioRobotics Corp shares, and 93.31% of them are in the hands of institutional investors. The stock currently has a share float of 97.86%. Procept BioRobotics Corp stock is held by 391.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 14.1215% of the shares, which is about 7.29 million shares worth $445.33 million.
VANGUARD GROUP INC, with 9.2375% or 4.71 million shares worth $287.87 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.63 shares worth $102.12 million, making up 2.98% of all outstanding shares. On the other hand, Fidelity Growth Company Fund held roughly 1.32 shares worth around $82.72 million, which represents about 2.41% of the total shares outstanding.
